Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study.

Zhao L, Chen H, Cheng Z, Jiang H, Lu Y, Xiao J, Xiao X, Li Y, Yuan Y, Li X

Obesity (Silver Spring, Md.)28 May 2025Cited by 1 (Europe PMC)

PMID40437798DOI10.1002/oby.24306PepBankPUB-40437798

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity or overweight, tirzepatide significantly reduced body weight compared with placebo.
In plain wordsIn Chinese adults with obesity or overweight, tirzepatide reduced body weight more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody weight reduction versus placebo
Study
n = 177
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide also significantly reduced body weight, BMI, and waist circumference compared with placebo (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis (N = 177; tirzepatide 10 mg, n = 62; tirzepatide 15 mg, n = 57; placebo, n = 58), participants with greater weight reduction (greater than or equal to the median percentage loss at 12 and 24 weeks) showed significantly greater improvements in cardiometabolic markers.
Report a problemFND-4043779802
02HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity or overweight, tirzepatide significantly reduced BMI compared with placebo.
In plain wordsIn Chinese adults with obesity or overweight, tirzepatide lowered BMI more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBMI reduction versus placebo
Study
n = 177
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide also significantly reduced body weight, BMI, and waist circumference compared with placebo (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis (N = 177; tirzepatide 10 mg, n = 62; tirzepatide 15 mg, n = 57; placebo, n = 58), participants with greater weight reduction (greater than or equal to the median percentage loss at 12 and 24 weeks) showed significantly greater improvements in cardiometabolic markers.
Report a problemFND-4043779803
03HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity or overweight, tirzepatide significantly reduced waist circumference compared with placebo.
In plain wordsIn Chinese adults with obesity or overweight, tirzepatide reduced waist size more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference reduction versus placebo
Study
n = 177
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide also significantly reduced body weight, BMI, and waist circumference compared with placebo (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis (N = 177; tirzepatide 10 mg, n = 62; tirzepatide 15 mg, n = 57; placebo, n = 58), participants with greater weight reduction (greater than or equal to the median percentage loss at 12 and 24 weeks) showed significantly greater improvements in cardiometabolic markers.
Report a problemFND-4043779804
04HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity or overweight on tirzepatide, greater early weight reduction was associated with significantly greater improvements in cardiometabolic markers.
In plain wordsIn Chinese adults taking tirzepatide, people who lost more weight early had bigger improvements in heart and metabolic markers.
Peptide
Tirzepatide
Outcome
MixedCardiometabolic markers by early weight loss
Study
n: not reported in source
Comparator
Participants with less early weight loss
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
10 mg or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
In this post hoc analysis (N = 177; tirzepatide 10 mg, n = 62; tirzepatide 15 mg, n = 57; placebo, n = 58), participants with greater weight reduction (greater than or equal to the median percentage loss at 12 and 24 weeks) showed significantly greater improvements in cardiometabolic markers.
Report a problemFND-4043779801
05HumanRandomized controlled trialEfficacy outcome
In Chinese adults with obesity or overweight on tirzepatide, 37 participants reached a normal BMI by week 52.
In plain wordsIn Chinese adults taking tirzepatide, 37 people reached a normal BMI by week 52.
Peptide
Tirzepatide
Outcome
Not applicableParticipants reaching normal BMI at week 52
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg or 15 mg · 52 weeksAs given in this study (human).
Measurements
Participants with normal BMI
37 participants
week 52
Source sentences
Summary
At week 52, 37 participants achieved a normal BMI (18.5-24 kg/m², Chinese criteria)
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis (N = 177; tirzepatide 10 mg, n = 62; tirzepatide 15 mg, n = 57; placebo, n = 58), participants with greater weight reduction (greater than or equal to the median percentage loss at 12 and 24 weeks) showed significantly greater improvements in cardiometabolic markers.
Report a problemFND-4043779805
06HumanRandomized controlled trialEfficacy outcome
In a post hoc analysis of Chinese adults on tirzepatide, metabolic syndrome dropped from 21.6% at baseline to 0% at week 52; the abstract reports this in the same sentence as the 37 participants who reached a normal BMI.
In plain wordsIn the reported group of Chinese adults on tirzepatide, metabolic syndrome went from 21.6% at baseline to none at week 52.
Peptide
Tirzepatide
Outcome
DecreaseMetabolic syndrome prevalence change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
10 mg or 15 mg · 52 weeksAs given in this study (human).
Measurements
Metabolic syndrome prevalence, baseline
21.6%
baseline
Metabolic syndrome prevalence, week 52
0%
week 52
Source sentences
Summary
metabolic syndrome dropped from 21.6% at baseline to 0%.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis (N = 177; tirzepatide 10 mg, n = 62; tirzepatide 15 mg, n = 57; placebo, n = 58), participants with greater weight reduction (greater than or equal to the median percentage loss at 12 and 24 weeks) showed significantly greater improvements in cardiometabolic markers.
Report a problemFND-4043779806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.